Gilead shares dip after warning about hepatitis C drug interaction

March 23 (Reuters) - Gilead Sciences Inc shares slid 2 percent on Monday after the company warned about potentially fatal risks for patients being treated with its top-selling hepatitis c drugs who also take the potent heart drug amiodarone.